pots and tirzepatide Dr. Blitshteyn her research ream reported a patient with who improved on semaglutide (Ozempic). π§ While many patients with POTS, dysautonomia and Long COVID feel better on GLP-1 RAs Tirzepatide vs semaglutide for POTS
Description
The choice between the two depends on individual preference and convenience
This triple action aims to: Reduce appetite
For Established Aesthetic Practices: Opportunity : Expand to body treatments with a single platform, as Ultherapy PRIME covers both face and body
No insurance coverage
The Precision Peptide Genetic Test ($99 after first month) maps variants in GLP1R, MC4R, FTO, and GIPR pathways, revealing your appetite-regulation predisposition
Patients may choose immunotherapy or chemotherapy as the best treatment option based on ADRM1 level (55)
